Highly active antiretroviral therapy
Highly active antiretroviral therapy
复制标题
DOI：
10.1136/bmj.330.7504.1341
复制
发表时间：
2005-06
期刊：
影响因子：
--
通讯作者：
Filip Moerman;Alfons Van Gompel;Jan Nimmegeers;Johan Moerman
中科院分区：
文献类型：
--
作者：
Filip Moerman;Alfons Van Gompel;Jan Nimmegeers;Johan Moerman
在开始治疗前需要对心血管风险进行评估。在工业化国家，针对晚期HIV-1疾病的高效抗逆转录病毒治疗（HAART）的可用性大大提高了患者的预期寿命然而，抗病毒药物的终身承诺是值得期待的。此外，最近越来越多的证据表明，心脑血管事故可能严重损害受感染者的健康，2由此产生的发病率和死亡率已经结束了与HAART时代开始有关的无限乐观。在这里，我们着眼于在开始HAART之前评估和瞄准心血管疾病风险的重要性，并考虑这种风险对确定开始治疗的最佳时间的影响。对于感染HIV-1的人，与未感染的人相比，HAART可能大大增加心血管死亡的风险。
Cardiovascular risk needs to be assessed before starting treatment I n the industrialised world the availability of highly active antiretroviral treatment (HAART) for advanced HIV-1 disease has dramatically improved patients' life expectancy.1 However, an unfailing lifelong commitment to antiviral drugs is expected. Furthermore, recent evidence is mounting that cardiovascular and cerebrovascular accidents might seriously impair the health of infected individuals,2 and the resulting morbidity and mortality have put an end to the unlimited optimism that was associated with the beginning of the HAART era. Here we look at the importance of assessing and targeting the risk of cardiovascular disease before starting HAART and consider what effect this risk has on determining the best time to start treatment. For people infected with HIV-1, HAART may substantially increase the risk of cardiovascular mortality compared with non-infected individuals or …